Type of Study: Epidemiological

Sponsor / Support: GSK/LACOG

Primary Objectives: To evaluate the safety profile, including dose modifications, of niraparib in patients with advanced ovarian cancer in response following first-line platinum-based chemotherapy treated in a real-world setting within the EAP.

Design: This is a multicenter, retrospective and prospective (bi-directional) patient chart review, observational (non-interventional) study.

Sample Size: 105 patients

Principal Investigator: Dr. Angélica Nogueira Rodrigues

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT05857397